PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of nihpaAbout Author manuscriptsSubmit a manuscriptHHS Public Access; Author Manuscript; Accepted for publication in peer reviewed journal;
 
Pediatr Res. Author manuscript; available in PMC 2012 July 1.
Published in final edited form as:
PMCID: PMC3111902
NIHMSID: NIHMS287668

Poly(ADP-Ribose) Polymerase-1: A Novel Therapeutic Target in Necrotizing Enterocolitis

Abstract

Necrotizing enterocolitis (NEC) is the most common gastrointestinal disease of infancy, afflicting 11% of infants born 22–28 weeks gestational age. Both inflammation and oxidation may be involved in NEC pathogenesis through reactive nitrogen species production, protein oxidation and DNA damage. Poly(ADP-ribose) polymerase-1 (PARP-1) is a critical enzyme activated to facilitate DNA repair using nicotinamide adenine dinucleotide (NAD+) as a substrate. However, in the presence of severe oxidative stress and DNA damage, PARP-1 over-activation may ensue, depleting cells of NAD+ and ATP, killing them by metabolic catastrophe. Here we tested the hypothesis that NO dysregulation in intestinal epithelial cells during NEC leads to marked PARP-1 expression and that administration of a PARP-1 inhibitor (nicotinamide) attenuates intestinal injury in a newborn rat model of NEC. In this model, 56% of control pups developed NEC (any stage), versus 14% of pups receiving nicotinamide. Forty-four percent of control pups developed high-grade NEC (grades 3–4), whereas only 7% of pups receiving nicotinamide developed high-grade NEC. Nicotinamide treatment protects pups against intestinal injury incurred in the newborn rat NEC model. We speculate that PARP-1 over-activation in NEC may drive mucosal cell death in this disease and that PARP-1 may be a novel therapeutic target in NEC.

Introduction

Necrotizing enterocolitis (NEC) is the most common gastrointestinal disease of infancy, with population studies estimating the incidence of NEC at between 0.3 and 2.4 per 1000 live births in the United States, and afflicting up to 11% of all infants born 22–28 weeks gestation(1, 2). Mortality rates range from 20–44% in infants with birth weights <1500g and up to 20% in infants >2500g(3). Although first described in the 1800s, the mechanistic basis of NEC remains poorly understood despite years of basic science and clinical exploration(4). Factors in the newborn intestine modulating the innate immune response as well as the protective and toxic effects of the free radical nitric oxide (NO) have been postulated as possible contributors to the initiation and/or progression of NEC(5, 6).

Endogenous NO is generated during the enzymatic conversion of L-arginine to L-citrulline and is catalyzed by a family of enzymes known as NO synthases (NOS)(7, 8). Three NOS isoenzymes function in the gastrointestinal tract to produce NO: neuronal NOS (NOS1), inducible NOS (NOS2), and endothelial NOS (NOS3). The synthase most commonly implicated in NO dysregulation is NOS2(9). Excess or uncontrolled production of NO can shift it from a useful cellular signal to a toxic free radical(10). NO dysregulation promotes the formation of peroxynitrite, a highly reactive nitrogen species known to nitrate protein tyrosine residues and cause cellular oxidative damage to organelles and DNA(11).

Widespread NOS2 induction and protein nitration have been found in human NEC specimens(12). Following DNA damage due to oxidation, poly(ADP-ribose) polymerase-1 (PARP-1) is a critical enzyme activated to facilitate DNA repair (Figure 1). This enzyme uses NAD+ (nicotinamide adenine dinucleotide) as a substrate and attaches multiple ADP-ribose (PAR) units to itself and other acceptor proteins(13, 14). This poly(ADP-ribosyl)ation allows the acceptor proteins to selectively influence important cellular responses that enhance DNA repair(15). However, in the presence of severe cellular oxidative stress and DNA damage, over-activation of PARP-1 may ensue(16). This may lead to cell death by two possible mechanisms. First, significant PARP-1 activation may deplete the cells of NAD+/ATP, killing the cells by metabolic catastrophe(16). Cells with already low NAD+ stores may be more prone such as proliferating enterocytes in the crypts or cells entering apoptosis such as those at the villus tips(17). Second, in the presence of adequate cell energy stores, increased PARP-1 activation can lead to apoptosis via apoptotic inducing factor (AIF) from the mitochondria or by caspase dependant mechanisms(18).

Figure 1
Illustration of PARP-1 action after DNA damage. PARP-1 adds PAR units onto DNA repair proteins in order to facilitate DNA repair. This action requires NAD+ and ATP. Over-activation of PARP-1 may deplete the cell of NAD+ and ATP stores. Adapted from Schreiber ...

The importance of apoptosis during the evolution of NEC has been supported in multiple experiments(1923). However, at some point necrosis will ensue if the disease continues to progress. Thus, a mediator such as PARP-1 in an injured or activated cell may serve as a checkpoint or governor between the fate of cellular repair and the fate of cell death (via either apoptosis or necrosis), and may play a vital role in disease progression including necrotizing enterocolitis. Our objective was to test the hypothesis that NO dysregulation in the intestinal epithelial cell during NEC leads to marked PARP-1 expression, and that administration of a known PARP-1 inhibitor (nicotinamide) will attenuate intestinal injury in a newborn rat model of NEC.

Methods

Animals

Pregnant Sprague-Dawley rats (Harlan Laboratories Indianapolis, IN.) were obtained at gestation E16 and were allowed access to standard chow and water ad libitum until delivery of the pups via C-section at E21 (term). All animal studies were approved by The Research Institute at Nationwide Children’s Hospital’s Institutional Animal Care and Use Committee (IACUC).

Neonatal Rat NEC Model

Following delivery, rat pups were placed on the rat NEC model protocol as previously described(24, 25). Each pup was given enteral LPS (1 mg/Kg E. coli lipopolysaccharide) followed by enteral orogastric artificial feedings 6 times a day. The feedings consisted of 15 grams of Similac 60/40 powder (Ross Pediatrics, Columbus, OH) added to 75 mL Esbilac Liquid Milk Replacer (Pet-Ag, New Hampshire, IL), to provide 200 Kcal/Kg/day. Starting within 2–3 hours of delivery, pups were exposed to hypoxia (100% nitrogen) for 2 minutes followed immediately by exposure to hypothermia (10 minutes at 4° C) twice a day. Pups were sacrificed at 4 days of age or sooner if they developed evidence of distress, including increased work of breathing or lethargy. Following sacrifice, the intestines were removed and placed in 10% formalin for 24 hours followed by saline. Following fixation of the intestines with formalin, the intestine was placed in paraffin block, and histologic sections were prepared and stained with hematoxylin and eosin for further analysis.

Grading of intestinal injury

A previously established grading system was utilized to objectively determine the degree of observed intestinal injury(25, 26). The grading system was as follows: Grade 0, no evidence of intestinal injury; Grade 1, sloughing at the tips of the villi only; Grade 2, sloughing to the mid villous; Grade 3, necrosis of the entire villus; and Grade 4, necrosis of the intestinal wall that includes the entire villus extending into the submucosa. Two separate investigators blinded to the study graded each intestinal sample.

Enteral administration of NOS2 blocker or nicotinamide

The selective NOS2 inhibitor aminoguanidine (AG; 10mg/kg/day; Cayman Chemical, Ann Arbor, MI) (n=11) or vehicle (sterile water) (n=12) were administered per orogastric tube prior to the first feeding and then daily throughout the four-day protocol in animals in the aminoguanidine group. In a separate experiment, the PARP inhibitor nicotinamide (500 mg/kg/day; Sigma-Aldrich, St.Louis, MO.) (n=14) or vehicle (sterile water) (n=16) were administered per orogastric tube prior to the first feeding and then daily throughout the four-day protocol in animals in the nicotinamide group. AG and nicotinamide were suspended in sterile water for these experiments.

Human NEC sample collection

Human intestinal tissues obtained during operative procedures carried out at Nationwide Children’s Hospital (Columbus, OH) were utilized. Sample collection was approved by Nationwide Children’s Hospital Institutional Review Board. The operative procedures that provide tissue for this study occurred during the course of standard care for intestinal disease states (i.e., intestinal obstruction or NEC). The pathologist first examined the tissue and those portions required to make a pathologic diagnosis are placed in the proper fixative; the remaining tissue that normally would be discarded by the pathologist was then analyzed in this study. The sample is cut into two pieces. One piece is placed in 10% formalin for 24 hours followed by saline and the second was immediately frozen at −80° C for future use. For the purposes of this study, we used NEC specimens taken from the region of the resection margin. These tissues were not grossly necrotic and had evidence of viable proximal mucosa.

Intestinal Immunohistochemistry

Five micron sections from formalin fixed paraffin embedded ileal tissues from either human or rat species were mounted on slides, rehydrated in a graded series of alcohols and deparaffinized for immunohistochemical staining. Immunohistochemistry was performed using primary antibodies specific for NOS2 (Transduction Labs; 1:200), 3-nitrotyrosine (3-NT) (Millipore, Billerica, MA; 1:400), and PARP-1 (Trevigen, Helgerman, CT 1:1000), followed by biotinylated universal goat link secondary antibody (Biocare Medical, Concord, CA), followed by streptavidin-HRP (Biocare Medical) and diaminobenzadine (DAB) (Sigma) as the chromogen. Tissue sections were visualized with an Olympus Optical (Melville, NY) BX-40 microscope (40 × objective). Images were captured under identical lighting conditions and optical settings, and analyzed using image analysis software (Image Pro Plus, Media Cybernetics, Silver Springs, MD). In each image, two transmural regions (distal villus, proximal villus) were outlined and the staining intensities, measured as integrated optical density (IOD), were determined for each region.

Image Analysis

Images were captured using a research grade Olympus BX-40 microscope, a high-resolution color digital camera (Diagnostic Instruments, Sterling Hts, MI) and a Pentium 233 PC workstation, and analyzed using Image Pro Plus software (Media Cybernetics, MD). Separate methods have been developed that allow semi-quantitative determination of the extent of immunoreactivity of sections. For tissues exhibiting a more punctate staining pattern (commonly observed with NOS2 presence), the image analysis software provided an automated analysis tool that allows for counting of dark or light objects; these objects can be gated to discriminate very small or large (i.e. noncellular) debris based on pixel size. Images are segmented after extraction of the blue channel and conversion to gray scale as previously described (27, 28). We have previously utilized this method to quantify NOS2 positive cells in a cross section of ileum from newborn rats in a model of prenatal LPS exposure and also hyperoxia exposure(25, 27, 28).

The degree of 3-NT, NOS2, and PARP-1 staining in the mucosa of ileal tissues from rats with Grade 1 and 2 injury were analyzed. Focus was placed on these grades in order to represent the early transition to severe tissue injury and cell death. Also, the mucosal region is obliterated in severe NEC (Figure 2) (grades 3 and 4 injury in the newborn rat model). Thus, the proximal mucosa could not be evaluated in these grades of injury.

Figure 2
Comparison of human and rodent NEC. Shown are representative photomicrographs of both human intestinal tissues and rat intestinal tissues with NEC. The upper panels show healthy tissue in both species and the lower panels shows NEC in both species. These ...

Statistical Analyses

Data are expressed as means ± S.E.M. Comparative analyses were completed by Student t-test and Two-way ANOVA with Bonferroni post-tests to determine relative differences among our study groups. A P value < 0.05 was considered significant.

Results

Evidence of reactive nitrogen species formation in the rat NEC model

Digital image analysis showed evidence of increased 3-NT in the proximal mucosal region (Figure 3A) in tissues with Grade 1 or 2 injury, demonstrating an increased prevalence of nitrative cellular injury.

Figure 3
3-NT and PARP-1 expression in experimental NEC. A) 3-Nitrotyrosine staining in the proximal mucosa of pups exposed to experimental NEC. 3-NT staining increased as the degree of injury increased in this region (* = p<0.05 versus control; Two-Way ...

PARP-1 activation in the rat NEC model

We observed significant increases in PARP-1 in the same regions of tissue in which we observed protein nitration (Figure 3B). Additionally, there was a positive association of PARP-1 prevalence in the regions of highest protein nitration among the NEC tissues investigated (Figure 3C).

Inhibition of NOS2 reduces intestinal mucosal PARP-1 expression

NOS2 expression was unchanged with aminoguanidine treatment in the proximal mucosa. In contrast 3-NT and PARP expression were significantly decreased in the proximal mucosa of pups treated with aminoguanidine (Figure 4). While there was no significant difference in overall NEC between treatment and control, severe grades of injury were protected against (0% vs. 50%) (data not shown). These finding are consistent with those of other investigators(12).

Figure 4
Effects of aminoguanidine on NOS2, 3-NT and PARP-1 expression in experimental NEC. (A) NOS2 immunostaining was unchanged. In pups with grade 2 NEC, there was significantly less 3-NT (B) and PARP (C) immunostaining within the proximal mucosa of pups treated ...

Nicotinamide is protective against intestinal injury in a newborn rat model of NEC

Administration of nicotinamide was protective against the development of any NEC (p< 0.01) and also protected against more severe grades of injury (p< 0.02) (Table 1).

Table 1
Effect of nicotinamide on experimental NEC

PARP-1 expression is elevated in human intestinal tissue resected for NEC

In Figure 5A, panel A shows PARP-1 immunostaining in a specimen of small intestine from an infant with bowel obstruction whereas Panel B shows PARP-1 immunostaining in intestinal tissue resected from an infant with NEC. Note this is not severe NEC or markedly necrotic bowel since the mucosa is still present in this portion of the specimen. When quantified (n=17 for control with mean gestational age 29±4 wks and n=20 for diseased with mean gestational age 31±5 wks), PARP-1 immunostaining was significantly increased in the intestinal mucosa of human NEC specimens (Figure 5B).

Figure 5
PARP-1 expression in human NEC

Discussion

Our objective was to test the hypothesis that NO dysregulation in the intestinal epithelial cell during NEC leads to marked PARP-1 expression, and that treatment with a known PARP-1 inhibitor attenuates intestinal injury in a newborn rat model of NEC. Analyses revealed evidence of increased 3-NT in the proximal mucosal region, demonstrating an increased prevalence of nitrative cellular injury. PARP-1 immunostaining was significantly decreased in pups treated with AG and subjected to experimental NEC. It appears that PARP-1 activation is downstream from NOS2 induction, and that blocking the NOS2 enzyme can reduce mucosal PARP in this setting. These data strongly support the concepts developed in other disease states, specifically that reactive nitrogen species lead to PARP-1 activation. Note that the use of amioguanidine will not decrease transcription of NOS2 protein, but it will decrease the enzyme activity. Thus, the downstream effects of the enzyme are attenuated as we have demonstrated in these experiments and have been shown previously by Vicente et al as well as others(29). PARP-1 is a contributor to both disease progression and severity in other disease states including myocardial infarction and inflammatory bowel disease (3032). PARP-1 is therapeutic target in these disease states as well as others (33). Therefore, it is possible that treatment with a PARP-1 inhibitor may also attenuate intestinal injury in NEC.

Upon administration of the known PARP-1 inhibitor nicotinamide in our rat NEC model, both intestinal injury and PARP-1 expression were significantly decreased. Nicotinamide was chosen in these initial experiments due to its wide safety profile and known PARP-1 inhibitory effects(16). There are several other PARP-1 inhibitors in clinical trials for other disease states, including diabetes and cancer(33). However, nicotinamide does have other effects, such as attenuation of inflammation, which may also make it an ideal choice for a therapeutic in premature infants. These experiments demonstrate evidence that PARP-1 may play a role in newborn intestinal injury and inhibition of PARP-1 may be protective against NEC. However, due to other potential roles nicotinamide might play in protecting the newborn intestine from injury, our finding support our hypothesis but do not definitively prove PARP’s mechanistic role in NEC. Other studies have identified the elevation of PARP-1 in experimental models of NEC, but they only identified it as a marker for cell death(34). Studies to putatively define the role of PARP-1 in NEC using PARP-1 “knock out” and “knock down” models of newborn intestinal injury are warranted and on-going in our laboratory as well as optimizing the dosing of nicotinamide and newborn intestinal injury.

Our results also support the premise that PARP-1 may play a role in the events leading to enterocyte cell death during human NEC. PARP-1 is significantly elevated in human NEC specimens when compared to control newborn intestinal tissues. Specifically, PARP-1 expression was elevated in the NEC surgical specimens that still have a relatively intact intestinal mucosa. It is generally accepted that the intestinal injury incurred in NEC begins in the mucosa and propagates from there(25, 35, 36). This region of intestine is critical for restitution from the initial stages of NEC. If the diseased intestinal tissue was not removed, it is plausible that these tissues would have progressed to NEC since the majority of these samples were at the resection margins of a sample with a necrotic mid-section. Therefore, it is reasonable to hypothesize that PARP-1 may be acting as a gate keeper for enterocyte cell death during NEC. Multiple studies have shown the importance of apoptosis and early cell death in the progression of bowel injury in NEC(19, 23). Identifying mediators that determine this early decision by the cells for restitution or cell death may allow us to develop therapies to halt the progression of this disease and subsequently decrease the significant morbidities associated with NEC(3739).

In summary, PARP-1 may be an important effector of intestinal injury and cell death associated with NEC. Further exploration of its mechanistic role in NEC as well as its viability as a therapeutic target and its safety in future studies, is warranted.

Acknowledgments

This study was supported in part by NIH grant 1K23DK078909.

Abbreviations

3-NT
3-nitrotyrosine
AG
Aminoguanidine
IOD
integrated optical density
LPS
lipopolysaccharide
NEC
necrotizing enterocolitis
NOS2
inducible nitric oxide synthase
PARP-1
poly(ADP-ribose) polymerase-1

Footnotes

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

References

1. Christensen RD, Gordon PV, Besner GE. Can we cut the incidence of necrotizing enterocolitis in half--today? Fetal Pediatr Pathol. 2010;29:185–198. [PubMed]
2. Stoll BJ, Hansen NI, Bell EF, Shankaran S, Laptook AR, Walsh MC, Hale EC, Newman NS, Schibler K, Carlo WA, Kennedy KA, Poindexter BB, Finer NN, Ehrenkranz RA, Duara S, Sánchez PJ, O’Shea TM, Goldberg RN, Van Meurs KP, Faix RG, Phelps DL, Frantz ID, 3rd, Watterberg KL, Saha S, Das A, Higgins RD. Eunice Kennedy Shriver National Institute of Child Health and Human Development Neonatal Research Network. Neonatal outcomes of extremely preterm infants from the NICHD Neonatal Research Network. Pediatrics. 2010;126:443–456. [PMC free article] [PubMed]
3. Fitzgibbons SC, Ching Y, Yu D, Carpenter J, Kenny M, Weldon C, Lillehei C, Valim C, Horbar JD, Jaksic T. Mortality of necrotizing enterocolitis expressed by birth weight categories. J Pediatr Surg. 2009;44:1072–1075. discussion 1075–1076. [PubMed]
4. Obladen M. Necrotizing Enterocolitis - 150 years of fruitless search for the cause. Neonatology. 2009;96:203–210. [PubMed]
5. Potoka DA, Nadler EP, Upperman JS, Ford HR. Role of nitric oxide and peroxynitrite in gut barrier failure. World J Surg. 2002;26:806–811. [PubMed]
6. Potoka DA, Nadler EP, Zhou X, Zhang XR, Upperman JS, Ford HR. Inhibition of NF-kappaB by IkappaB prevents cytokine-induced NO production and promotes enterocyte apoptosis in vitro. Shock. 2000;14:366–373. [PubMed]
7. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med. 1993;329:2002–2012. [PubMed]
8. Sessa WC. The nitric oxide synthase family of proteins. J Vasc Res. 1994;31:131–143. [PubMed]
9. Stuehr DJ, Marletta MA. Mammalian nitrate biosynthesis: mouse macrophages produce nitrite and nitrate in response to Escherichia coli lipopolysaccharide. Proc Natl Acad Sci USA. 1985;82:7738–7742. [PubMed]
10. Pryor WA, Squadrito GL. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am J Physiol. 1995;268:L699–L722. [PubMed]
11. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. 1996;271:C1424–C1437. [PubMed]
12. Zamora R, Bryan NS, Boyle P, Wong C, Milsom AB, Jaffe R, Feelisch M, Ford HR. Nitrosative stress in an animal model of necrotizing enterocolitis. Free Radic Biol Med. 2005;39:1428–1437. [PubMed]
13. Schreiber V, Dantzer F, Ame JC, de Murcia G. Poly(ADP-ribose): novel functions for an old molecule. Nat Rev Mol Cell Biol. 2006;7:517–528. [PubMed]
14. Szabo C, Pacher P, Swanson RA. Novel modulators of poly(ADP-ribose) polymerase. Trends Pharmacol Sci. 2006;27:626–630. [PMC free article] [PubMed]
15. Meyer-Ficca ML, Meyer RG, Jacobson EL, Jacobson MK. Poly(ADP-ribose) polymerases: managing genome stability. Int J Biochem Cell Biol. 2005;37:920–926. [PubMed]
16. Szabó C. Poly(ADP-ribose) polymerase activation by reactive nitrogen species--relevance for the pathogenesis of inflammation. Nitric Oxide. 2006;14:169–179. [PubMed]
17. Hassa PO, Haenni SS, Elser M, Hottiger MO. Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going? Microbiol Mol Biol Rev. 2006;70:789–829. [PMC free article] [PubMed]
18. Kolthur-Seetharam U, Dantzer F, McBurney MW, de Murcia G, Sassone-Corsi P. Control of AIF-mediated cell death by the functional interplay of SIRT1 and PARP-1 in response to DNA damage. Cell Cycle. 2006;5:873–877. [PubMed]
19. Jilling T, Lu J, Jackson M, Caplan MS. Intestinal epithelial apoptosis initiates gross bowel necrosis in an experimental rat model of neonatal necrotizing enterocolitis. Pediatr Res. 2004;55:622–629. [PubMed]
20. Hunter CJ, Singamsetty VK, Chokshi NK, Boyle P, Camerini V, Grishin AV, Upperman JS, Ford HR, Prasadarao NV. Enterobacter sakazakii enhances epithelial cell injury by inducing apoptosis in a rat model of necrotizing enterocolitis. J Infect Dis. 2008;198:586–593. [PMC free article] [PubMed]
21. Clark JA, Lane RH, Maclennan NK, Holubec H, Dvorakova K, Halpern MD, Williams CS, Payne CM, Dvorak B. Epidermal growth factor reduces intestinal apoptosis in an experimental model of necrotizing enterocolitis. Am J Physiol Gastrointest Liver Physiol. 2005;288:G755–G762. [PubMed]
22. Leaphart CL, Cavallo J, Gribar SC, Cetin S, Li J, Branca MF, Dubowski TD, Sodhi CP, Hackam DJ. A critical role for TLR4 in the pathogenesis of necrotizing enterocolitis by modulating intestinal injury and repair. J Immunol. 2007;179:4808–4820. [PubMed]
23. Feng J, El-Assal ON, Besner GE. Heparin-binding epidermal growth factor-like growth factor reduces intestinal apoptosis in neonatal rats with necrotizing enterocolitis. J Pediatr Surg. 2006;41:742–747. discussion 742–747. [PubMed]
24. Caplan MS, Sun XM, Hseuh W, Hageman JR. Role of platelet activating factor and tumor necrosis factor-alpha in neonatal necrotizing enterocolitis. J Pediatr. 1990;116:960–964. [PubMed]
25. Giannone PJ, Nankervis CA, Richter JM, Schanbacher BL, Reber KM. Prenatal lipopolysaccharide increases postnatal intestinal injury in a rat model of necrotizing enterocolitis. J Pediatr Gastroenterol Nutr. 2009;48:276–282. [PubMed]
26. Caplan MS, Hedlund E, Adler L, Hsueh W. Role of asphyxia and feeding in a neonatal rat model of necrotizing enterocolitis. Pediatr Pathol. 1994;14:1017–1028. [PubMed]
27. Giannone PJ, Bauer JA, Schanbacher BL, Reber KM. Effects of hyperoxia on postnatal intestinal development. Biotech Histochem. 2007;82:17–22. [PubMed]
28. Giannone PJ, Schanbacher BL, Bauer JA, Reber KM. Effects of prenatal lipopolysaccharide exposure on epithelial development and function in newborn rat intestine. J Pediatr Gastroenterol Nutr. 2006;43:284–290. [PubMed]
29. Vicente AM, Guillen MI, Habib A, Alcaraz MJ. Beneficial effects of heme oxygenase-1 up-regulation in the development of experimental inflammation induced by zymosan. J Pharmacol Exp Ther. 2003;307:1030–1037. [PubMed]
30. Szabó C. Pharmacological inhibition of poly(ADP-ribose) polymerase in cardiovascular disorders: future directions. Curr Vasc Pharmacol. 2005;3:301–303. [PubMed]
31. Sánchez-Fidalgo S, Villegas I, Martín A, Sánchez-Hidalgo M, Alarcón de la Lastra C. PARP inhibition reduces acute colonic inflammation in rats. Eur J Pharmacol. 2007;563:216–223. [PubMed]
32. Beneke S. Poly(ADP-ribose) polymerase activity in different pathologies--the link to inflammation and infarction. Exp Gerontol. 2008;43:605–614. [PubMed]
33. Gerö D, Szabó C. Poly(ADP-ribose) polymerase: a new therapeutic target? Curr Opin Anaesthesiol. 2008;21:111–121. [PubMed]
34. Baregamian N, Rychahou PG, Hawkins HK, Evers BM, Chung DH. Phosphatidylinositol 3-kinase pathway regulates hypoxia-inducible factor-1 to protect from intestinal injury during necrotizing enterocolitis. Surgery. 2007;142:295–302. [PMC free article] [PubMed]
35. Chokshi NK, Guner YS, Hunter CJ, Upperman JS, Grishin A, Ford HR. The role of nitric oxide in intestinal epithelial injury and restitution in neonatal necrotizing enterocolitis. Semin Perinatol. 2008;32:92–99. [PMC free article] [PubMed]
36. Yu X, Radulescu A, Zorko N, Besner GE. Heparin-binding EGF-like growth factor increases intestinal microvascular blood flow in necrotizing enterocolitis. Gastroenterology. 2009;137:221–230. [PMC free article] [PubMed]
37. Horwitz JR, Lally KP, Cheu HW, Vazquez WD, Grosfeld JL, Ziegler MM. Complications after surgical intervention for necrotizing enterocolitis: a multicenter review. J Pediatr Surg. 1995;30:994–998. discussion 8–9. [PubMed]
38. Hintz SR, Kendrick DE, Stoll BJ, Vohr BR, Fanaroff AA, Donovan EF, Poole WK, Blakely ML, Wright L, Higgins R. NICHD Neonatal Research Network. Neurodevelopmental and growth outcomes of extremely low birth weight infants after necrotizing enterocolitis. Pediatrics. 2005;115:696–703. [PubMed]
39. Rees CM, Pierro A, Eaton S. Neurodevelopmental outcomes of neonates with medically and surgically treated necrotizing enterocolitis. Arch Dis Child Fetal Neonatal Ed. 2007;92:F193–F198. [PMC free article] [PubMed]